

Highlights of This Issue 2283

SMALL MOLECULE THERAPEUTICS

- | | | | |
|------|---|------|--|
| 2285 | <p>Identification of Preferred Chemotherapeutics for Combining with a <i>CHK1</i> Inhibitor
Yang Xiao, Judi Ramiscal, Kaska Kowanetz, Christopher Del Nagro, Shiva Malek, Marie Evangelista, Elizabeth Blackwood, Peter K. Jackson, and Thomas O'Brien</p> | 2356 | <p>AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models
Tammy L. Bush, Marc Payton, Scott Heller, Grace Chung, Kelly Hanestad, James B. Rottman, Robert Loberg, Gregory Friberg, Richard L. Kendall, Douglas Saffran, and Robert Radinsky</p> |
| 2296 | <p>Gramicidin A Induces Metabolic Dysfunction and Energy Depletion Leading to Cell Death in Renal Cell Carcinoma Cells
Justin M. David, Tori A. Owens, Sonali P. Barwe, and Ayyappan K. Rajasekaran</p> | 2367 | <p>UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia <i>In Vitro</i> and <i>In Vivo</i>
Sandra Christoph, Deborah DeRyckere, Jennifer Schlegel, J. Kimble Frazer, Lance A. Batchelor, Alesia Y. Trakhimets, Susan Sather, Debra M. Hunter, Christopher T. Cummings, Jing Liu, Chao Yang, Dmitri Kireev, Catherine Simpson, Jacqueline Norris-Drouin, Emily A. Hull-Ryde, William P. Janzen, Gary L. Johnson, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp III, and Douglas K. Graham</p> |
| 2308 | <p>Developing Lipid Nanoparticle-Based siRNA Therapeutics for Hepatocellular Carcinoma Using an Integrated Approach
Leiming Li, Rongqi Wang, Denise Wilcox, Aparna Sarthy, Xiaoyu Lin, Xiaoli Huang, Lu Tian, Prasad Dande, Robert D. Hubbard, Todd M. Hansen, Carol Wada, Xiaobin Zhao, William M. Kohlbrenner, Stephen W. Fesik, and Yu Shen</p> | 2378 | <p>SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis
Takeshi Masuda, Noboru Hattori, Tadashi Senoo, Shin Akita, Nobuhisa Ishikawa, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, and Nobuoki Kohno</p> |
| 2319 | <p>BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu, Bruce R. Rowley, Cathy O. Bull, Claudia Schneider, Andrea Haegerbarth, Christoph A. Schatz, Paul R. Fracasso, Dean P. Wilkie, Martin Hentemann, Scott M. Wilhelm, William J. Scott, Dominik Mumberg, and Karl Ziegelbauer</p> | 2389 | <p>Paclitaxel-Hyaluronic NanoConjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model
Rajendar K. Mittapalli, Xinli Liu, Chris E. Adkins, Mohamed I. Nounou, Kaci A. Bohn, Tori B. Terrell, Hussaini S. Qhattal, Werner J. Geldenhuys, Diane Palmieri, Patricia S. Steeg, Quentin R. Smith, and Paul R. Lockman</p> |
| 2331 | <p>PRIMA-1^{Met}/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Manujendra N. Saha, Hua Jiang, Yijun Yang, Donna Reece, and Hong Chang</p> | 2400 | <p>Isolation of a Novel Thioflavin S-Derived Compound That Inhibits BAG-1-Mediated Protein Interactions and Targets BRAF Inhibitor-Resistant Cell Lines
Marion Enthammer, Emmanouil S. Papadakis, Maria Salomé Gachet, Martin Deutsch, Stefan Schwaiger, Katarzyna Koziel, Muhammad Imtiaz Ashraf, Sana Khalid, Gerhard Wolber, Graham Packham, Ramsey I. Cutress, Hermann Stuppner, and Jakob Troppmair</p> |
| 2342 | <p>Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i>
Christian Thomas, Francois Lamoureux, Claire Crafter, Barry R. Davies, Eliana Beraldi, Ladan Fazli, Soojin Kim, Daksh Thaper, Martin E. Gleave, and Amina Zoubeidi</p> | | |

- 2415 **The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants**
Michaela Medová, Benoît Pochon, Bruno Streit, Wieslawa Blank-Liss, Paola Francica, Deborah Stroka, Adrian Keogh, Daniel M. Aebersold, Andree Blaukat, Friedhelm Blatt, and Yitzhak Zimmer
- 2425 **Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer**
Huifang Li, Mohamed D.H. Hassona, Nathan A. Lack, Peter Axerio-Cilies, Eric Leblanc, Peyman Tavassoli, Natalia Kanaan, Kate Frewin, Kriti Singh, Hans Adomat, Konrad J. Böhm, Helge Prinz, Emma Tomlinson Guns, Paul S. Rennie, and Artem Cherkasov
- 2436 **¹⁷⁷Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy**
Josefine Reber, Stephanie Haller, Christopher P. Leamon, and Cristina Müller
- 2446 **MTI-101 (Cyclized HYD1) Binds a CD44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma**
Anthony W. Gebhard, Priyesh Jain, Rajesh R. Nair, Michael F. Emmons, Raul F. Argilagos, John M. Koomen, Mark L. McLaughlin, and Lori A. Hazlehurst

LARGE MOLECULE THERAPEUTICS

- 2459 **A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity**
 Shane A. Olwill, Christian Joffroy, Hendrik Gille, Elisa Vigna, Gabriele Matschiner, Andrea Allersdorfer, Bradley M. Lunde, Jakub Jaworski, James F. Burrows, Cristina Chiriaco, Hans Jürgen Christian, Martin Hülsmeier, Stefan Trentmann, Kristian Jensen, Andreas M. Hohlbaum, and Laurent Audoly
- 2472 **Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γ H2AX**
Bart Cornelissen, Andrew Waller, Sarah Able, and Katherine A. Vallis

CANCER THERAPEUTICS INSIGHTS

- 2483 **The Cannabinoid WIN 55,212-2 Decreases Specificity Protein Transcription Factors and the Oncogenic Cap Protein eIF4E in Colon Cancer Cells**
Sandeep Sreevalsan and Stephen Safe
- 2494 ***In Vitro* and *In Vivo* Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome**
Liang Zhang, Lan V. Pham, Kate J. Newberry, Zhishuo Ou, Rong Liang, Jianfei Qian, Luhong Sun, Marzenna Blonska, Yun You, Jing Yang, Xin Lin, Alex Rollo, Archito T. Tamayo, John Lee, Richard J. Ford, Xiurong Zhao, Larry W. Kwak, Qing Yi, and Michael Wang
- 2505 **Attenuation of Argininosuccinate Lyase Inhibits Cancer Growth via Cyclin A2 and Nitric Oxide**
Hau-Lun Huang, Hui-Ping Hsu, Shu-Chu Shieh, Yung-Sheng Chang, Wei-Ching Chen, Chien-Yu Cho, Chiao-Fang Teng, Ih-Jen Su, Wen-Chun Hung, and Ming-Derg Lai
- 2517 **PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy**
Jeremy P.H. Chow, Wing Yu Man, Mao Mao, Han Chen, Florence Cheung, John Nicholls, Sai Wah Tsao, Maria Li Lung, and Randy Y.C. Poon
- 2529 **Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylating Anticancer Drug Temozolomide**
Marcus Eich, Wynand Paul Roos, Teodora Nikolova, and Bernd Kaina
- 2541 **Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib**
Keith M. Giles, Felicity C. Kalinowski, Patrick A. Candy, Michael R. Epis, Priscilla M. Zhang, Andrew D. Redfern, Lisa M. Stuart, Gregory J. Goodall, and Peter J. Leedman
- 2559 **Hsp90 Inhibitors Promote p53-Dependent Apoptosis through PUMA and Bax**
Kan He, Xingnan Zheng, Lin Zhang, and Jian Yu

2569

miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4

Gang Zhao, Bo Wang, Yang Liu, Jun-gang Zhang, Shi-chang Deng, Qi Qin, Kui Tian, Xiang Li, Shuai Zhu, Yi Niu, Qiong Gong, and Chun-you Wang

2581

Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction

Yan Long, Wen-Bin Tsai, Medhi Wangpaichitr, Takashi Tsukamoto, Niramol Savaraj, Lynn G. Feun, and Macus Tien Kuo

2591

Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage

Hae-June Lee, Changhwan Yoon, Benjamin Schmidt, Do Joong Park, Alexia Y. Zhang, Hayriye V. Erkizan, Jeffrey A. Toretsky, David G. Kirsch, and Sam S. Yoon

TOOLS AND TECHNOLOGIES

2601

Capillary Isoelectric-Focusing Immunoassays to Study Dynamic Oncoprotein Phosphorylation and Drug Response to Targeted Therapies in Non-Small Cell Lung Cancer

Jin-Qiu Chen, Jih-Hsiang Lee, Michelle A. Herrmann, Kang-Seo Park, Madeleine R. Heldman, Paul K. Goldsmith, Yisong Wang, and Giuseppe Giaccone

LETTER TO THE EDITOR

2614


EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter

Pei Jye Voon, Dana Wai Yi Tsui, Nitzan Rosenfeld, and Tan Min Chin

AC icon indicates Author Choice

For more information please visit www.aacrjournals.org**ABOUT THE COVER**

Ribbon representation of a homology model of the c-Met specific Anticalin PRS-110. Anticalins are engineered human lipocalins that represent a next generation class of drug molecules. The lipocalins have a structurally conserved β -barrel architecture that forms a cup-shaped ligand binding pocket that can accommodate small and large ligands. The β strands (blue) of the lipocalin form the base of the ligand-binding pocket and the entry of the pocket is comprised of four loops connecting the β strands. Novel, target-specific Anticalins are generated by engineering mutations (pink regions, PRS-110 mutations) within these four loops and then selecting variants with the desired binding activity. For details, see article by Olwill and colleagues on page 2459.



Molecular Cancer Therapeutics

12 (11)

Mol Cancer Ther 2013;12:2283-2615.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/12/11>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/12/11>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.